blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2658872

EP2658872 - A POLYPEPTIDE THAT BINDS ABERRANT CELLS AND INDUCES APOPTOSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.08.2021
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  28.08.2020
FormerGrant of patent is intended
Status updated on  05.04.2020
FormerExamination is in progress
Status updated on  02.10.2017
Most recent event   Tooltip22.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 24.08.2022  [2022/34]
Applicant(s)For all designated states
Apo-T B.V.
Stadsring 181
3817 BA Amersfoort / NL
For all designated states
Willemsen, Ralph Alexander
Mathenesserlaan 467-A
3023 GK Rotterdam / NL
For all designated states
Renes, Johan
Het Binnenhof 7
3818 LW Amersfoort / NL
[2013/45]
Inventor(s)01 / WILLEMSEN, Ralph Alexander
Mathenesserlaan 467-A
NL-3023 GK Rotterdam / NL
02 / RENES, Johan
Het Binnenhof 7
NL-3818 LW Amersfoort / NL
 [2013/45]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2013/45]
Application number, filing date11820898.222.12.2011
[2020/40]
WO2011NL50891
Priority number, dateUS201061460212P27.12.2010         Original published format: US 201061460212 P
[2013/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012091563
Date:05.07.2012
Language:EN
[2012/27]
Type: A1 Application with search report 
No.:EP2658872
Date:06.11.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 05.07.2012 takes the place of the publication of the European patent application.
[2013/45]
Type: B1 Patent specification 
No.:EP2658872
Date:30.09.2020
Language:EN
[2020/40]
Search report(s)International search report - published on:EP05.07.2012
ClassificationIPC:C07K16/28, C07K16/30, A61P35/00
[2013/45]
CPC:
C07K16/2833 (EP,US); A61K47/64 (US); A61K45/06 (US);
A61K47/6851 (US); A61P35/00 (EP); C07K16/30 (EP,US);
C07K2317/21 (EP,US); C07K2317/24 (EP,US); C07K2317/32 (EP,US);
C07K2317/34 (EP,US); C07K2317/35 (EP,US); C07K2317/55 (EP,US);
C07K2317/56 (EP,US); C07K2317/73 (EP,US); C07K2319/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/45]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ABERRANTE ZELLEN BINDENDES UND APOPTOSE INDUZIERENDES POLYPEPTID[2013/45]
English:A POLYPEPTIDE THAT BINDS ABERRANT CELLS AND INDUCES APOPTOSIS[2013/45]
French:POLYPEPTIDE SE LIANT À DES CELLULES ABERRANTES ET INDUISANT L'APOPTOSE[2013/45]
Entry into regional phase26.06.2013National basic fee paid 
26.06.2013Designation fee(s) paid 
26.06.2013Examination fee paid 
Examination procedure26.06.2013Examination requested  [2013/45]
12.02.2014Amendment by applicant (claims and/or description)
16.09.2014Despatch of a communication from the examining division (Time limit: M06)
22.04.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
29.06.2015Reply to a communication from the examining division
20.06.2016Despatch of a communication from the examining division (Time limit: M04)
24.10.2016Reply to a communication from the examining division
21.09.2017Despatch of a communication from the examining division (Time limit: M04)
19.01.2018Reply to a communication from the examining division
11.09.2018Despatch of a communication from the examining division (Time limit: M06)
15.03.2019Reply to a communication from the examining division
24.02.2020Cancellation of oral proceeding that was planned for 10.03.2020
10.03.2020Date of oral proceedings (cancelled)
06.04.2020Communication of intention to grant the patent
14.08.2020Fee for grant paid
14.08.2020Fee for publishing/printing paid
14.08.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20195939.2  / EP3778642
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.09.2014
Opposition(s)01.07.2021No opposition filed within time limit [2021/36]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
29.06.2015Request for further processing filed
29.06.2015Full payment received (date of receipt of payment)
Request granted
10.07.2015Decision despatched
Fees paidRenewal fee
11.12.2013Renewal fee patent year 03
21.10.2014Renewal fee patent year 04
21.12.2015Renewal fee patent year 05
14.06.2017Renewal fee patent year 06
27.12.2017Renewal fee patent year 07
02.10.2018Renewal fee patent year 08
31.12.2019Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.12.201606   M06   Fee paid on   14.06.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.12.2011
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
MK30.09.2020
MT30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
TR30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
BE31.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
[2022/34]
Former [2022/32]HU22.12.2011
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
MK30.09.2020
MT30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
TR30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2022/27]HU22.12.2011
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
MT30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
TR30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2022/26]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
TR30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2022/23]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2022/10]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
PT01.02.2021
Former [2022/08]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
DK31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/52]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
CH31.12.2020
FR31.12.2020
GR31.12.2020
LI31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/49]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
SE23.12.2020
BG30.12.2020
GB30.12.2020
NO30.12.2020
FR31.12.2020
GR31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/48]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
BG30.12.2020
NO30.12.2020
FR31.12.2020
GR31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/47]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
LU22.12.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/46]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
IE22.12.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/43]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
NL01.01.2021
IS30.01.2021
PT01.02.2021
Former [2021/40]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/28]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/25]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/24]AT30.09.2020
CZ30.09.2020
EE30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RO30.09.2020
RS30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/23]CZ30.09.2020
EE30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RO30.09.2020
RS30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/22]CZ30.09.2020
EE30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RO30.09.2020
RS30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/21]FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RS30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/20]FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RS30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
Former [2021/10]FI30.09.2020
HR30.09.2020
LV30.09.2020
RS30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
Former [2021/08]FI30.09.2020
BG30.12.2020
NO30.12.2020
Former [2021/07]FI30.09.2020
NO30.12.2020
Cited inInternational search[A]WO02079222  (LEADD BV [NL], et al) [A] 1-21 * the whole document *;
 [XI]WO2005120166  (TECHNION RES & DEV FOUNDATION [IL], et al) [X] 1,12-17,19-21 * the whole document * [I] 2-11,18;
 [XI]WO2007073147  (UNIV ERASMUS MEDICAL CT [NL], et al) [X] 1,12-17,19 * the whole document * [I] 2-11,18;
 [XI]WO2008120202  (TECHNION RES & DEV FOUNDATION [IL], et al) [X] 1,12-17,19-21 * the whole document * [I] 2-11,18;
 [A]  - RALPH WILLEMSEN ET AL, "Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy", CYTOMETRY PART A, (20081101), vol. 73A, no. 11, doi:10.1002/cyto.a.20644, ISSN 1552-4922, pages 1093 - 1099, XP055028814 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1002/cyto.a.20644
 [A]  - RA WILLEMSEN ET AL, "A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes", GENE THERAPY, (20011101), vol. 8, no. 21, doi:10.1038/sj.gt.3301570, ISSN 0969-7128, pages 1601 - 1608, XP055028813 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.gt.3301570
ExaminationWO2007073147
 WO2009131435
    - Claude Backendorf ET AL, "Apoptin: Therapeutic Potential of an Early Sensor of Carcinogenic Transformation", Annual Review of Pharmacology and Toxicology, (20080201), vol. 48, no. 1, doi:10.1146/annurev.pharmtox.48.121806.154910, ISSN 0362-1642, pages 143 - 169, XP055139454

DOI:   http://dx.doi.org/10.1146/annurev.pharmtox.48.121806.154910
    - H-Y ZHANG ET AL, "Tumor-targeted delivery of biologically active TRAIL protein", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 17, doi:10.1038/CGT.2009.76, ISSN 0929-1903, (20100501), pages 334 - 343, (20100115), XP002660326

DOI:   http://dx.doi.org/10.1038/cgt.2009.76
    - STIEGLMAIER JULIA ET AL, "Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 57, no. 2, doi:10.1007/S00262-007-0370-8, ISSN 0340-7004, (20080201), pages 233 - 246, (20070731), XP002528355

DOI:   http://dx.doi.org/10.1007/S00262-007-0370-8
    - P Bruno ET AL, "Family at last: highlights of the first international meeting on proteins killing tumour cells", CELL DEATH AND DIFFERENTIATION., GB, (20090101), vol. 16, no. 1, doi:10.1038/cdd.2008.164, ISSN 1350-9047, pages 184 - 186, XP055407217

DOI:   http://dx.doi.org/10.1038/cdd.2008.164
    - NOY R ET AL, "T-CELL RECEPTOR-LIKE ANTIBODIES: NOVEL REAGENTS FOR CLINICAL CANCER IMMUNOLOGY AND IMMUNOTHERAPY", EXPERT REVIEW OF ANTICANCER THE, EXPERT REVIEWS LTD, GB, (20050601), vol. 5, no. 3, doi:10.1586/14737140.5.3.523, ISSN 1473-7140, pages 523 - 536, XP009067037

DOI:   http://dx.doi.org/10.1586/14737140.5.3.523
by applicantWO02079222
 WO2004050705
 WO2007073147
    - PEDERSEN AE ET AL., EXP CELL RES., (1999), vol. 251, pages 128 - 34
    - CAO Y ET AL., BR J HAEMATOL., (2011), vol. 154, pages 111 - 121
    - MARCAR L ET AL., CANCER RES, (2010), vol. 70, pages 10362 - 10370
    - D.K. MCCURDY ET AL., J. RHEUMATOL., (2002), vol. 29, pages 2219 - 2224
    - WILLEMSEN RA ET AL., CYTOMETRY A, (2008), vol. 73, pages 1093 - 1099
    - RENKVIST, N. ET AL., CANCER IMMUNOL. IMMUNOTHER, (2001), vol. 50, pages 3 - 15
    - ANTICANCER RESEARCH, (2006), vol. 26, pages 1513 - 1518
    - STEPHANIE GRAFF-DUBOIS; OLIVIER FAURE; DAVID-ALEXANDRE GROSS; PEDRO ALVES; ANTONIO SCARDINO; SALEM CHOUAIB; FRANCOIS A. LEMONNIER;, "Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy", THE JOURNAL OF IMMUNOLOGY, (2002), vol. 169, pages 575 - 580, XP001109368
    - HANS J. DE HAARD; NICOLE VAN NEER; ANNEKE REURS; SIMON E. HUFTON; ROB C. ROOVERS; PAULA HENDERIKX; ADRIAAN P. DE BRUME; JAN-WILLEM, "A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1999), vol. 274, doi:doi:10.1074/jbc.274.26.18218, pages 18218 - 18230, XP002128301

DOI:   http://dx.doi.org/10.1074/jbc.274.26.18218
    - "Selection of antigens against biotinylated antigens. In Antibody phage display, methods and protocols", CHAMES P; H.R. HOOGENBOOM; P. HENDERIKX, Methods in Molecular Biology, (2002), vol. 178, pages 147 - 159
    - PATRICK CHAMES; SIMON E. HUFTON; PIERRE G. COULIE; BARBARA UCHANSKA-ZIEGLER; HENNIE R. HOOGENBOOM, "Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-Al-MAGE-Al from a nonimmunized phage-Fab library", PNAS, (2000), vol. 97, doi:doi:10.1073/pnas.97.14.7969, pages 7969 - 7974, XP002967292

DOI:   http://dx.doi.org/10.1073/pnas.97.14.7969
    - MATHIEU H.M. NOTEBORN, "Proteins selectively killing tumor cells", EUR. J. PHARMACOL., (2009), vol. 625, doi:doi:10.1016/j.ejphar.2009.06.068, pages 165 - 173, XP026762259

DOI:   http://dx.doi.org/10.1016/j.ejphar.2009.06.068
    - DANEN-VAN OORSCHOT A. A. A. M.; D. F. FISCHER; J. M. GRIMBERGEN; B. KLEIN; S.-M. ZHUANG; J. H. F. FALKENBURG; C. BACKENDORF; P. H., "Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells", PROCEEDINGS NATIONAL ACADEMY SCIENCES, (1997), vol. 94, doi:doi:10.1073/pnas.94.11.5843, pages 5843 - 5847, XP002052232

DOI:   http://dx.doi.org/10.1073/pnas.94.11.5843
    - LI X; JIN N; MI Z; LIAN H; SUN L; LI X; ZHENG H, "Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro", INT J CANCER, (2006), vol. 119, no. 12, pages 2948 - 57
    - OLIJSLAGERS SJ; ZHANG YH; BACKENDORF C; NOTEBORN MH, "Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells", BASIC CLIN PHARMACOL TOXICOL., (2007), vol. 100, no. 2, pages 127 - 31
    - PEDERSEN AE; BREGENHOLT S; JOHANSEN B; SKOV S; CLAESSON MH, "MHC-I-induced apoptosis in human B-lymphoma cells is dependent on protein tyrosine and serine/threonine kinases", EXP CELL RES., (1999), vol. 251, pages 128 - 34
    - CAO Y; LAN Y; QIAN J; ZHENG Y; HONG S; LI H; WANG M; KWAK LW; LIN D; YANG J, "Targeting cell surface ?2 -microglobulin by pentameric IgM antibodies", BR J HAEMATOL, (2011), vol. 154, pages 111 - 121
    - MCCURDY DK; TAI LQ; IMFELD KL; SCHWARTZ M; ZALDIVAR F; BERMAN MA, "Expression of melanoma antigen gene by cells from inflamed joints in juvenile rheumatoid arthritis", J RHEUMATOL., (2002), vol. 29, pages 2219 - 2224, XP009098385
    - MARCAR L; MACLAINE NJ; HUPP TR; MEEK DW, "Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin", CANCER RES, (2010), vol. 70, pages 10362 - 10370
    - WILLEMSEN RA; CHAMES P; SCHOOTEN E; GRATAMA JW; DEBETS R, "Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy", CYTOMETRY A, (2008), vol. 73, doi:doi:10.1002/cyto.a.20644, pages 1093 - 1099, XP055028814

DOI:   http://dx.doi.org/10.1002/cyto.a.20644
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.